Read the latest reports on Western Europe, with local insight, sp...
Read the latest reports on Western Europe, with local insight, specialist knowledge and a comprehensive breakdown of key market data. Our research identifies key strategic themes relevant across the region, while also providing a more granular unders...
Sales of analgesics are seeing robust growth in current value terms in 2023, continuing on from the steady performance seen in 2022. During 2022, sales of analgesics benefited from a sudden peak in cases of flu in the middle of the winter. This was…
Following strong growth between 2020 and 2022, analgesics saw much more moderate current value growth in 2023 as the COVID-19 pandemic began to wane. Rising inflation as a result of the energy crisis stemming in part from the war in Ukraine is…
Value sales of analgesics in France continue to record solid growth in 2023 following a dynamic performance the previous year. The key growth driver is the increasing demand for acetaminophen, with the brand Doliprane from Sanofi, convincingly…
Upon the lifting of all COVID-19 related regulations, including the compulsory use of face masks, social distancing rules and compulsory self-isolation, there has been a surge in illness which has been a major contributor to sales growth for…
Analgesics sales are returning to more normal patterns in 2023, following the fluctuations caused by the COVID-19 pandemic and the sharp price rises seen in 2022. On balance, current value growth rates are still elevated compared to pre-pandemic…